• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

NIDCR's Fall 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   NIDCR News 5 Q&As About “Oral Health in America: Advances and Challenges” NIDCR issued a brief Q&A regarding details of the forthcoming report Oral Health in America: Advances and Challenges, which will be published in Fall 2021. This comprehensive report will examine improvements in oral health over the past two decades,...
Source: NIDCR Science News - September 1, 2021 Category: Dentistry Source Type: news

Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
CONCLUSIONS: The pCR rate with decreased intensity of therapy with 60 Gy of IMRT and weekly low-dose cisplatinum is very high in favorable-risk oropharyngeal squamous cell carcinoma, with evidence of decreased toxicity compared with standard therapies. ClinicalTrials.gov ID: NCT01530997. PMID: 26581135 [PubMed - in process]
Source: Medical Physics - November 21, 2015 Category: Physics Authors: Chera BS, Amdur RJ, Tepper J, Qaqish B, Green R, Aumer SL, Hayes N, Weiss J, Grilley-Olson J, Zanation A, Hackman T, Funkhouser W, Sheets N, Weissler M, Mendenhall W Tags: Int J Radiat Oncol Biol Phys Source Type: research

Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)
Conclusion The recommended phase II dose for nab-paclitaxel is 60 mg/m2 weekly when given standard weekly cetuximab and concurrent IMRT. This regimen merits further study as a nonplatinum alternative to IMRT + cetuximab alone. Clinicaltrials.gov ID NCT00736619.
Source: Annals of Oncology - February 24, 2014 Category: Cancer & Oncology Authors: Fury, M. G., Sherman, E. J., Rao, S. S., Wolden, S., Smith-Marrone, S., Mueller, B., Ng, K. K., Dutta, P. R., Gelblum, D. Y., Lee, J. L., Shen, R., Kurz, S., Katabi, N., Haque, S., Lee, N. Y., Pfister, D. G. Tags: head and neck tumors Source Type: research

Onycholemmal carcinoma: A morphologic comparison of 6 reported cases
Conclusions: Onycholemmal carcinoma is a distinct type of squamous cell carcinoma arising from the nail isthmus; its natural clinical course is indolent. In this regard less aggressive digit-sparing treatment modalities such as radiation or Mohs micrographic surgery should be considered.
Source: Journal of the American Academy of Dermatology - August 22, 2012 Category: Dermatology Authors: Brad E. Chaser, Krystal M. Renszel, A. Neil Crowson, Anita Osmundson, Igor V. Shendrik, Edward H. Yob, G. Scott Drew, Paul R. Callegari, Shannon Campbell, Jan V. Pitha, Cynthia M. Magro Tags: Original Articles Source Type: research